OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Ip on the Impact of BCMA Alternative Splicing in Lymphoma and Multiple Myeloma

June 24th 2024

Andrew Ip, MD, discusses alternative splicing of the TNFRSF17 gene, which encodes BCMA, in patients with lymphoma or multiple myeloma.

Dr El-Khoueiry on Regorafenib/Pembrolizumab in Advanced HCC After Prior Anti–PD-1/L1 Therapy

June 24th 2024

Anthony B. El-Khoueiry, MD, on data for regorafenib plus pembrolizumab in pretreated advanced hepatocellular carcinoma.

Dr King on the Need for Less-Toxic Therapies in Advanced Gastrointestinal Cancers

June 24th 2024

Daniel King, MD, PhD, discusses the need to develop less-toxic regimens for advanced gastrointestinal cancers.

Dr Lenz on Frontline Nivolumab Plus Ipilimumab in MSI-H/dMMR mCRC

June 21st 2024

Heinz-Josef Lenz, MD, FACP, discusses updated data for nivolumab plus ipilimumab in MSI-H/dMMR mCRC.

Dr Yilmaz on HB-200 Arenavirus Plus Pembrolizumab in HPV16+ Head and Neck Cancer

June 21st 2024

Emrullah Yilmaz, MD, PhD, discusses HB-200 arenavirus–based immunotherapy plus pembrolizumab in recurrent/metastatic HPV16+ head and neck cancer.

Dr Grimm on Post-Progression OS After Darolutamide Plus ADT/Docetaxel in mHSPC

June 21st 2024

Marc-Oliver Grimm, MD discusses darolutamide in combination with androgen deprivation therapy and docetaxel in mHSPC.

Dr Winer on the Rationale for the TakeAim Leukemia Trial in Mutated AML

June 21st 2024

Eric Winer, MD, discusses the rationale for the phase 1/2a TakeAim Leukemia trial of emavusertib in patients with R/R FLT3- and spliceosome-mutated AML.

Dr Lai on NCCN Guideline Updates in AML Maintenance Therapy

June 21st 2024

Catherine E. Lai, MD, MPH, discusses NCCN guideline updates regarding AML maintenance therapy, sharing how these updates influence treatment decisions.

Dr Braun on Biopsy Site Selection in Biomarker Testing in ccRCC

June 21st 2024

David Braun, MD, PhD, discusses findings from the molecular analysis of the HCRN GU16-260-Cohort A study.

Dr Maluf on Pembrolizumab Plus Platinum-Based Chemotherapy in Advanced Penile Cancer

June 21st 2024

Fernando C. Maluf, MD, PhD discusses the efficacy of platinum-based chemotherapy plus pembrolizumab in advanced penile squamous cell carcinoma.

Dr Al Malki on Outcomes With PTCy-Based GVHD Prophylaxis in Hematologic Malignancies

June 21st 2024

Monzr M. Al Malki, MD, discusses outcomes with mismatched unrelated donor transplantation using post-transplant cyclophosphamide–based GVHD prophylaxis.

Dr Jimenez Jimenez on PBSC from HLA-Mismatched Donors in Hematological Malignancies

June 21st 2024

Antonio Martin Jimenez Jimenez, MD, discusses conditioning therapy, PBSC from HLA-MMUD, and PTCy for GVHD prophylaxis in hematological malignancies.

Dr Serzan on the Potential of Botensilimab/Balstilimab to Address Unmet Needs in RCC

June 21st 2024

Michael Serzan, MD, discusses the use of botensilimab/balstilimab in the treatment of patients with advanced renal cell carcinoma.

Dr Li on Patient Outcomes From the KEYNOTE-057 Trial in BCG-Unresponsive NMIBC

June 20th 2024

Roger Li, MD, discusses patient outcomes from the KEYNOTE-057 trial in BCG–unresponsive, high-risk non–muscle-invasive bladder cancer.

Dr Deininger on Long-Term Outcomes With Ponatinib in T315I-Mutant CP-CML

June 20th 2024

Michael Deininger, MD, PhD, discusses 4-year outcomes with ponatinib in patients with chronic myeloid leukemia harboring a T315I mutation.

Dr Pant on the Utility of Zanidatamab in Previously Treated HER2+ Biliary Tract Cancer

June 20th 2024

Shubham Pant, MD, MBBS, discusses the utility of zanidatamab in patients with previously treated HER2+ biliary tract cancer.

Dr Kirtane on an Investigation of TILs Plus Pembrolizumab in Advanced HNSCC

June 20th 2024

Kedar Kirtane, MD, discusses a phase 1b study of TBio-4101 plus pembrolizumab in patients with PD-1 inhibitor–resistant, advanced HNSCC.

Dr Winter on Real-World Outcomes With Liso-Cel in Richter Transformation

June 20th 2024

Allison Winter, MD, discusses data from a retrospective analysis evaluating real-world outcomes with liso-cel in patients with Richter transformation.

Dr Mattes on the Mechanism of Action of Ipatasertib in HNSCC

June 20th 2024

Malcolm Mattes, MD, discusses the CTEP 10492 trial of ipatasertib plus chemoradiotherapy in locally advanced head and neck squamous cell carcinoma.

Dr Tarantino on Updated Survival Data With T-DXd in HER2+ Breast Cancer

June 19th 2024

Paolo Tarantino, MD, discusses updated data from the phase 3 DESTINY-Breast03 trial of trastuzumab deruxtecan in HER2-positive breast cancer.